



June 26, 2026

Dear U.S. TED Community,

We understand how important it is to keep the community informed about our efforts to develop potential new treatment options for people living with thyroid eye disease (TED). As requested by the community, we are writing with news that the U.S. Food and Drug Administration (FDA) has approved veligrotug for the treatment of TED regardless of TED activity or duration. Veligrotug will be known under its brand name Lumvoa™ (veligrotug-vvze).

Please continue reading for Indication and Important Safety Information, and please see the read the full Prescribing Information at <https://www.lumvoa.com/content/lumvoa-prescribing-information.pdf>

We are grateful to all within the community for the countless conversations, shared stories, feedback and insights, and collaboration. We are also thankful for the those involved in the various clinical trials studying Lumvoa, including the hundreds of individuals living with TED who participated. We share this milestone with you and celebrate our collective achievement.

Indication and Important Safety Information for Lumvoa

INDICATION



Lumvoa is indicated for the treatment of Thyroid Eye Disease regardless of Thyroid Eye Disease activity or duration.

IMPORTANT SAFETY INFORMATION

Infusion Reactions: Lumvoa may cause infusion reactions. Infusion reactions have been reported in approximately 9% of patients treated with Lumvoa. Signs and symptoms of infusion-related reactions include transient increases in blood pressure, fever, chills, headache, and fatigue. Infusion reactions may occur during or soon after an infusion. Reported infusion reactions are usually mild or moderate in severity and can usually be successfully managed with corticosteroids, antihistamines, and antipyretics. In patients who experience an infusion reaction, consideration should be given to standard premedication and/or administering infusions at a slower infusion rate.

Inflammatory Bowel Disease: Lumvoa may cause an exacerbation of inflammatory bowel disease (IBD). IBD has been reported in some patients receiving insulin-like growth factor-1 receptor inhibitors without a prior diagnosis of IBD. Monitor patients for signs and symptoms of IBD, including patients without a history of IBD. If IBD is suspected, discontinue use of Lumvoa.

Hyperglycemia: Hyperglycemia or increased blood glucose may occur in patients treated with Lumvoa. In clinical trials, 12% of

patients, of whom one-half had preexisting diabetes or impaired glucose tolerance, experienced hyperglycemia. Hyperglycemic events should be controlled with medications for glycemic control, if necessary. Assess patients for elevated blood glucose and symptoms of hyperglycemia prior to infusion and continue to monitor while on treatment with Lumvoa. Ensure patients with hyperglycemia or preexisting diabetes are under appropriate glycemic control before and while receiving Lumvoa. Continued monitoring after treatment is recommended for patients who experience hyperglycemia while on Lumvoa.

Hearing Impairment Including Hearing Loss: Lumvoa may cause severe hearing impairment including hearing loss, which in some cases may be permanent. Assess patients' hearing before, during, and after treatment with Lumvoa and consider the benefit-risk of treatment with patients.

Most Common Adverse Events: Most common adverse reactions (incidence of 5% or more) are muscle spasms, headache, hearing impairment, hyperglycemia, fatigue, diarrhea, ear discomfort, infusion-related reaction, nausea, nasopharyngitis, blood creatine phosphokinase increased, dry skin, and hypertension.

Females of Reproductive Potential: Appropriate forms of contraception should be implemented prior to initiation, during treatment, and for 6 months following the last dose of Lumvoa. Lumvoa (500 mg) is an injection for infusion.



Please see the full Prescribing Information

<https://www.lumvoa.com/content/lumvoa-prescribing-information.pdf>

These are not all of the possible side effects of Lumvoa. For more information on the risk and benefits profile of Lumvoa, please speak your healthcare provider. You may report side effects to the FDA at 1-800-FDA-1088

or <https://www.accessdata.fda.gov/scripts/medwatch/index.cfm>

This information is not intended to replace discussions with a healthcare provider. Please speak with a healthcare professional for all medical questions.

Thank you on behalf of Viridian Team,

Jennifer Helfer

Senior Director, Patient Advocacy & Engagement